{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:16:03Z","timestamp":1789690563970,"version":"4.0.1"},"reference-count":142,"publisher":"FapUNIFESP (SciELO)","issue":"2 suppl 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An. Bras. Dermatol."],"DOI":"10.1590\/abd1806-4841.2019940207","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T19:48:16Z","timestamp":1559418496000},"page":"33-47","source":"Crossref","is-referenced-by-count":50,"title":["Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology"],"prefix":"10.1590","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3650-4254","authenticated-orcid":false,"given":"Claudia Giuli","family":"Santi","sequence":"first","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2217-6704","authenticated-orcid":false,"given":"Alexandre Carlos","family":"Gripp","sequence":"additional","affiliation":[{"name":"Universidade do Estado do Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2709-1825","authenticated-orcid":false,"given":"Ana Maria","family":"Roselino","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5458-1451","authenticated-orcid":false,"given":"Danielle Santana","family":"Mello","sequence":"additional","affiliation":[{"name":"Universidade do Estado do Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-5808","authenticated-orcid":false,"given":"Juliana Olivieri","family":"Gordilho","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0081-654X","authenticated-orcid":false,"given":"Paula Figueiredo de","family":"Marsillac","sequence":"additional","affiliation":[{"name":"Universidade do Estado do Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0736-4790","authenticated-orcid":false,"given":"Adriana Maria","family":"Porro","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2019,4]]},"reference":[{"key":"ref1","series-title":"Tratado de Dermatologia","first-page":"417","volume-title":"Dermatoses Vesicobolhosas Autoimunes","author":"Aoki V","year":"2014","edition":"2. ed"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00403-014-1531-1","article-title":"Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid","volume":"307","author":"Alpsoy E","year":"2015","journal-title":"Arch Dermatol Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan SM","year":"2008","journal-title":"BMJ"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2133.2000.03661.x","article-title":"IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis","volume":"143","author":"Christophoridis S","year":"2000","journal-title":"Br J Dermatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1046\/j.1523-1747.2003.12146.x","article-title":"Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid","volume":"120","author":"Dimson OG","year":"2003","journal-title":"J Invest Dermatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3389\/fimmu.2018.00407","article-title":"The Autoimmune Skin Disease Bullous Pemphigoid: The Role of Mast Cells in Autoantibody-Induced Tissue Injury","volume":"9","author":"Fang H","year":"2018","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/bjd.15924","article-title":"IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants","volume":"177","author":"Freire PC","year":"2017","journal-title":"Br J Dermatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of Disease: Pemphigus and Bullous Pemphigoid","volume":"11","author":"Hammers CM","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/bjd.15416","article-title":"Clinical significance of immunoglobulin E in bullous pemphigoid","volume":"177","author":"Hammers CM","year":"2017","journal-title":"Br J Dermatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.14889","article-title":"Induced autoimmune bullous diseases","volume":"176","author":"Hashimoto T","year":"2017","journal-title":"Br J Dermatol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/jamadermatol.2016.4593","article-title":"Immunoglobulin E Autoantibodies in Bullous Pemphigoid Detected by Immunoglobulin E Enzyme-Linked Immunosorbent Assays","volume":"153","author":"Hashimoto T","year":"2017","journal-title":"JAMA Dermatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjd.15114","article-title":"Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid","volume":"177","author":"Hashimoto T","year":"2017","journal-title":"Br J Dermatol"},{"key":"ref13","article-title":"Circulating anti-bullous pemphigoid 180 autoantibody can be detected in a wide clinical spectrum: A cross-sectional study","author":"Liu Z","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.3389\/fimmu.2017.01752","article-title":"BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid","volume":"8","author":"Liu Y","year":"2017","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jid.2017.11.031","article-title":"Eosinophils Mediate Tissue Injury in the Autoimmune Skin Disease Bullous Pemphigoid","volume":"138","author":"Lin L","year":"2018","journal-title":"J Invest Dermatol"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107725","article-title":"Human eosinophils express the high affinity IgE receptor, FceRI, in bullous pemphigoid","volume":"9","author":"Messingham KN","year":"2014","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jdermsci.2015.01.013","article-title":"In vivo analysis of IgE autoantibodies in bullous pemphigoid: a study of 100 cases","volume":"78","author":"Moriuchi R","year":"2015","journal-title":"J Dermatol Sci"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jdermsci.2013.12.001","article-title":"Update on the pathogenesis of bullous pemphigoid: an autoantibody- mediated blistering disease targeting collagen XVII","volume":"73","author":"Nishie W","year":"2014","journal-title":"J Dermatol Sci"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00403-017-1789-1","article-title":"IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review","volume":"310","author":"Saniklidou AH","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/bjd.14821","article-title":"Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A","volume":"176","author":"Ren Z","year":"2017","journal-title":"Br J Dermatol"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1111\/ajd.12764","article-title":"Association between bullous pemphigoid and malignancy: A meta-analysis","author":"Lucariello RJ","year":"2018","journal-title":"Australas J Dermatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.clindermatol.2013.01.006","article-title":"Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies","volume":"31","author":"Lo Schiavo A","year":"2013","journal-title":"Clin Dermatol"},{"key":"ref23","series-title":"Dermatology","first-page":"475","volume-title":"Pemphigoid Group","author":"Bernard P","year":"2012","edition":"3rd ed"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/jid.2010.301","article-title":"Risk factors for bullous pemphigoid in the elderly: a prospective case-control study","volume":"131","author":"Bastuji-Garin S","year":"2011","journal-title":"J Invest Dermatol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1684\/ejd.2010.0805","article-title":"Bullous pemphigoid and internal diseases - A case-control study","volume":"20","author":"Jedlickova H","year":"2010","journal-title":"Eur J Dermatol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000106574","article-title":"Neurological disorders in patients with bullous pemphigoid","volume":"215","author":"Cordel N","year":"2007","journal-title":"Dermatology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/jdv.13660","article-title":"Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis","volume":"30","author":"Lai YC","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1590\/abd1806-4841.20153334","article-title":"Bullous pemphigoid and neurological disease: statistics from a dermatology service","volume":"90","author":"Tarazona MJ","year":"2015","journal-title":"An Bras Dermatol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1590\/abd1806-4841.20142516","article-title":"Bullous pemphigoid and comorbidities: a case-control study in Portuguese patients","volume":"89","author":"Teixeira VB","year":"2014","journal-title":"An Bras Dermatol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/jdv.12136","article-title":"Immunopathological characteristics of patients with bullous pemphigoid and neurological disease","volume":"28","author":"Taghipour K","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref31","first-page":"179","article-title":"Bullous Pemphigoid Associated with Ischemic Cerebrovascular Accident and Dementia: Exclusive Blistering Lesions on the Upper Hemiparetic Limb","volume":"26","author":"Vernal S","year":"2018","journal-title":"Acta Dermatovenerol Croat"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1684\/ejd.2017.3066","article-title":"The association between bullous pemphigoid and neurological disorders: a systematic review","volume":"27","author":"Milani-Nejad N","year":"2017","journal-title":"Eur J Dermatol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/exd.13401","article-title":"Neurological and psychiatric associations in bullous pemphigoid-more than skin deep?","volume":"26","author":"F\u00f6rsti AK","year":"2017","journal-title":"Exp Dermatol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.semcdb.2017.06.005","article-title":"BPAG1, a distinctive role in skin and neurological diseases","volume":"69","author":"Ali A","year":"2017","journal-title":"Semin Cell Dev Biol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jid.2016.09.010","article-title":"Increased Levels of the Bullous Pemphigoid BP180 Autoantibody Are Associated with More Severe Dementia in Alzheimer's Disease","volume":"137","author":"Kokkonen N","year":"2017","journal-title":"J Invest Dermatol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s12026-018-9028-1","article-title":"Biological predictors shared by dementia and bullous pemphigoid patients point out a cross-antigenicity between BP180\/BP230 brain and skin isoforms","volume":"66","author":"Julio TA","year":"2018","journal-title":"Immunol Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5021\/ad.2018.30.1.8","article-title":"HLA-C*17, DQB1*03:01, DQA1*01:03 and DQA1*05:05 Alleles Associated to Bullous Pemphigoid in Brazilian Population","volume":"30","author":"Chagury AA","year":"2018","journal-title":"Ann Dermatol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/tan.12960","article-title":"A multi-hit hypothesis of bullous pemphigoid and associated neurological disease: Is HLA-DQB1*03:01, a potential link between immune privileged antigen exposure and epitope spreading?","volume":"89","author":"Amber KT","year":"2017","journal-title":"HLA"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt E","year":"2013","journal-title":"Lancet"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1590\/abd1806-4841.20143221","article-title":"Immunofluorescence testing in the diagnosis of autoimmune blistering diseases: overview of 10-year experience","volume":"89","author":"Arbache ST","year":"2014","journal-title":"An Bras Dermatol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1346-8138.12703","article-title":"Importance of serological tests in diagnosis of autoimmune blistering diseases","volume":"42","author":"Ishii K","year":"2015","journal-title":"J Dermatol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/ijd.13834","article-title":"Anti-desmogleins autoantibodies detected by ELISA and blotting in bullous pemphigoid: what do they mean?","volume":"57","author":"Julio T","year":"2018","journal-title":"Int J Dermatol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology","volume":"172","author":"Feliciani C","year":"2015","journal-title":"Br J Dermatol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/exd.13444","article-title":"Variation of the epidermal expression of glucocorticoid receptor-beta as potential predictive marker of bullous pemphigoid outcome","volume":"26","author":"Brulefert A","year":"2017","journal-title":"Exp Dermatol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/exd.13408","article-title":"Glucocorticoids: The mode of action in bullous pemphigoid","volume":"26","author":"Kubin ME","year":"2017","journal-title":"Exp Dermatol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/jdv.12155","article-title":"Treatment of bullous pemphigoid with low- dose oral cyclophosphamide: a case series of 20 patients","volume":"28","author":"Gual A","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jid.2017.01.028","article-title":"Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016","volume":"137","author":"Schmidt E","year":"2017","journal-title":"J Invest Dermatol"},{"key":"ref48","first-page":"672","article-title":"Treatment of bullous pemphigoid with rituximab: critical analysis of the current literature","volume":"12","author":"Shetty S","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.molmed.2013.06.003","article-title":"Emerging treatments for pemphigoid diseases","volume":"19","author":"Ludwig RJ","year":"2013","journal-title":"Trends Mol Med"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1529-8019.2002.01549.x","article-title":"Cicatricial pemphigoid: immunopathogenesis and treatment","volume":"15","author":"Lazarova Z","year":"2002","journal-title":"Derm Ther"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12026-017-8975-2","article-title":"Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations","volume":"66","author":"Kridin K","year":"2018","journal-title":"Immunol Res"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.det.2011.03.011","article-title":"Pathogenesis of mucous membrane pemphigoid","volume":"29","author":"Kourosh AS","year":"2011","journal-title":"Dermatol Clin"},{"key":"ref53","first-page":"370","article-title":"The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators","volume":"138","author":"Chan LS","year":"2002","journal-title":"Arch Dermatol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/08916934.2011.606447","article-title":"Pemphigoid diseases: pathogenesis, diagnosis, and treatment","volume":"45","author":"Kasperkiewicz M","year":"2012","journal-title":"Autoimmunity"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cden.2013.07.003","article-title":"Mucous Membrane Pemphigoid","volume":"57","author":"Xu HH","year":"2013","journal-title":"Dent Clin North Am"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0738-081X(00)00196-6","article-title":"Mucous membrane pemphigoid","volume":"19","author":"Chan LS","year":"2001","journal-title":"Clin Dermatol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1067\/moe.2003.5","article-title":"Modification to the approach of the diagnosis of mucous membrane pemphigoid: A case report and literature review","volume":"95","author":"Parisi E","year":"2003","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"ref58","first-page":"565","article-title":"Mucous membrane pemphigoid with severe esophageal stricture","volume":"86","author":"Barbosa Ldo N","year":"2011","journal-title":"An Bras Dermatol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2014.08.024","article-title":"Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts","volume":"72","author":"Murrell DF","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1529-8019.2010.01323.x","article-title":"The management of mucous membrane pemphigoid and pemphigus","volume":"23","author":"Knudson RM","year":"2010","journal-title":"Dermatol Ther"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1067\/moe.2003.139","article-title":"Treatment of severe erosive gingival lesions by topical application of clobetasol propionate in custom trays","volume":"95","author":"Gonzalez-Moles MA","year":"2003","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"ref62","first-page":"56","article-title":"Management and prevention of recurrent herpes labialis in immunocompetent patients","volume":"14","author":"Gilbert SC","year":"2007","journal-title":"Herpes"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archinte.168.11.1137","article-title":"The treatment of herpes simplex infections: an evidence-based review","volume":"168","author":"Cernik C","year":"2008","journal-title":"Arch Intern Med"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1365-2230.2004.01619.x","article-title":"Topical tacrolimus for oral cicatricial pemphigoid","volume":"29","author":"Assmann T","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1754-4505.2006.tb01512.x","article-title":"Successful treatment of mucous membrane pemphigoid with tacrolimus","volume":"26","author":"Suresh L","year":"2006","journal-title":"Spec Care Dentist"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2340\/00015555-1142","article-title":"Oral mucous membrane pemphigoid: complete response to topical tacrolimus","volume":"91","author":"Lee HY","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.det.2011.06.022","article-title":"Therapeutic approaches to patients with mucous membrane pemphigoid","volume":"29","author":"Kourosh AS","year":"2011","journal-title":"Dermatol Clin"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1600-0714.2008.00653.x","article-title":"The management of oral mucous membrane pemphigoid with dapsone and topical corticosteroid","volume":"37","author":"Arash A","year":"2008","journal-title":"J Oral Pathol Med"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/11310740-000000000-00000","article-title":"Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data","volume":"10","author":"G\u00fcrcan HM","year":"2009","journal-title":"Am J Clin Dermatol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1684\/ejd.2010.0847","article-title":"Dapsone efficacy and adverse events in the management of mucous membrane pemphigoid","volume":"20","author":"Hegarty AM","year":"2010","journal-title":"Eur J Dermatol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1067\/mjd.2001.114746","article-title":"Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent","volume":"45","author":"Megahed M","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/ICO.0b013e31826af7b8","article-title":"Treatment of mucous membrane pemphigoid with mycophenolate mofetil","volume":"32","author":"Nottage JM","year":"2013","journal-title":"Cornea"},{"key":"ref73","series-title":"Comprehensive Dermatologic Drug Therapy","first-page":"197","volume-title":"Cytotoxic agents","author":"Perlis C","year":"2007","edition":"2nd ed"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ophtha.2003.07.010","article-title":"Methotrexate therapy for ocular cicatricial pemphigoid","volume":"111","author":"McCluskey P","year":"2004","journal-title":"Ophthalmology"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2147\/TCRM.S1140","article-title":"Treatment strategies in mucous membrane pemphigoid","volume":"4","author":"Neff AG","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1365-2133.2008.08876.x","article-title":"Effect of folic or folinic acid supplementation on methotrexate- associated safety and efficacy in inflammatory disease: a systematic review","volume":"160","author":"Prey S","year":"2009","journal-title":"Br J Dermatol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/bjd.12041","article-title":"Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid","volume":"168","author":"Munyangango EM","year":"2013","journal-title":"Br J Dermatol"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/1735-1995.183992","article-title":"The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature","volume":"21","author":"Tavakolpour S","year":"2016","journal-title":"J Res Med Sci"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1001\/archderm.137.9.1181","article-title":"Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy","volume":"137","author":"Ahmed AR","year":"2001","journal-title":"Arch Dermatol"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archdermatol.2011.54","article-title":"Rituximab for patients with refractory mucous membrane pemphigoid","volume":"147","author":"Le Roux-Villet C","year":"2011","journal-title":"Arch Dermatol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1590\/abd1806-4841.20131905","article-title":"Off-label use of rituximab in dermatology: pemphigus treatment","volume":"88","author":"Bomm L","year":"2013","journal-title":"An Bras Dermatol"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1067\/mjd.2001.119100","article-title":"Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept","volume":"46","author":"Sacher C","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/archderm.142.11.1457","article-title":"Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients","volume":"142","author":"Canizares MJ","year":"2006","journal-title":"Arch Dermatol"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archderm.142.10.1268","article-title":"Successful treatment of mucous membrane pemphigoid with infliximab","volume":"142","author":"Heffernan MP","year":"2006","journal-title":"Arch Dermatol"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-4632.2009.03886.x","article-title":"Epidermolysis bullosa acquisita: concise review and practical considerations","volume":"48","author":"Lehman JS","year":"2009","journal-title":"Int J Dermatol"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/archderm.1990.01670260041007","article-title":"Epidermolysis bullosa acquisita. Incidence in patients with basement membrane zone antibodies","volume":"126","author":"Zhu XJ","year":"1990","journal-title":"Arch Dermatol"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12026-017-8975-2","article-title":"Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations","volume":"66","author":"Kridin K","year":"2018","journal-title":"Immunol Res"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/jdv.12096","article-title":"Epidermolysis bullosa acquisita","volume":"27","author":"Kim JH","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clindermatol.2011.03.011","article-title":"Epidermolysis bullosa acquisita","volume":"30","author":"Gupta R","year":"2012","journal-title":"Clin Dermatol"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/JID.2015.356","article-title":"Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options","volume":"136","author":"Kasperkiewicz M","year":"2016","journal-title":"J Invest Dermatol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/1744666X.2016.1196136","article-title":"Clinical and immunological studies for 105 Japanese seropositive patients of epidermolysis bullosa acquisita examined at Kurume University","volume":"12","author":"Hashimoto T","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"812029","DOI":"10.1155\/2013\/812029","article-title":"Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita","volume":"2013","author":"Ludwig RJ","year":"2013","journal-title":"ISRN Dermatol"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/08916934.2011.606450","article-title":"Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen","volume":"45","author":"Chen M","year":"2012","journal-title":"Autoimmunity"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/1744666X.2016.1221343","article-title":"Clinical features and diagnosis of epidermolysis bullosa acquisita","volume":"13","author":"Vorobyev A","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1097\/DAD.0000000000000829","article-title":"Epidermolysis Bullosa Acquisita (Brunsting-Perry Pemphigoid Variant) Localized to the Face and Diagnosed With Antigen Identification Using Skin Deficient in Type VII Collagen","volume":"39","author":"Asfour L","year":"2017","journal-title":"Am J Dermatopathol"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jaad.2017.11.029","article-title":"Serration pattern analysis for differentiating epidermolysis bullosa acquisita from other pemphigoid diseases","volume":"78","author":"M Meijer JM","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"ref97","doi-asserted-by":"crossref","DOI":"10.4081\/dr.2011.e38","article-title":"Epidermolysis bullosa acquisita: current diagnosis and therapy","volume":"3","author":"Mehren CR","year":"2011","journal-title":"Dermatol Reports"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaad.2012.01.016","article-title":"A consensus approach to wound care in epidermolysis bullosa","volume":"67","author":"Pope E","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref99","first-page":"CD004056","article-title":"Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita","author":"Kirtschig G","year":"2003","journal-title":"C Cochrane Database Syst Rev"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1346-8138.2009.00799.x","article-title":"Epidermolysis bullosa acquisita: what's new?","volume":"37","author":"Ishii N","year":"2010","journal-title":"J Dermatol"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/bjd.13144","article-title":"Epidermolysis bullosa acquisita: a retrospective analysis of 12 patients evaluated in four tertiary hospitals in Spain","volume":"171","author":"Iranzo P","year":"2014","journal-title":"Br J Dermatol"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2340\/00015555-1065","article-title":"Epidermolysis bullosa acquisita: a retrospective clinical analysis of 30 cases","volume":"91","author":"Kim JH","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.det.2011.06.020","article-title":"Management of epidermolysis bullosa acquisita","volume":"29","author":"Intong LR","year":"2011","journal-title":"Dermatol Clin"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2230.2010.03845.x","article-title":"Clinical and immunopathological evaluation of epidermolysis bullosa acquisita","volume":"36","author":"Delgado L","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1517\/14656566.2011.549127","article-title":"Current concepts in the treatment of epidermolysis bullosa acquisita","volume":"12","author":"G\u00fcrcan HM","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4103\/0019-5154.182420","article-title":"Childhood Epidermolysis Bullosa Acquisita: Confirmation of Diagnosis by Skin Deficient in Type VII Collagen, Enzyme-linked Immunosorbent Assay, and Immunoblotting","volume":"61","author":"Goyal N","year":"2016","journal-title":"Indian J Dermatol"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1525-1470.2011.01509.x","article-title":"Childhood epidermolysis bullosa acquisita: report of a Chinese case","volume":"29","author":"Yang B","year":"2012","journal-title":"Pediatr Dermatol"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11318600-000000000-00000","article-title":"Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management","volume":"27","author":"Mutasim DF","year":"2010","journal-title":"Drugs Aging"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.15896","article-title":"Colchicine: an ancient drug with novel applications","volume":"178","author":"D Dasgeb B","year":"2018","journal-title":"Br J Dermatol"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/1346-8138.13395","article-title":"Oral colchicine monotherapy for epidermolysis bullosa acquisita: Mechanism of action and efficacy","volume":"43","author":"Adachi A","year":"2016","journal-title":"J Dermatol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.clindermatol.2011.03.015","article-title":"Treatment of subepidermal immunobullous diseases","volume":"30","author":"Culton DA","year":"2012","journal-title":"Clin Dermatol"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2340\/00015555-1804","article-title":"Inflammatory epidermolysis bullosa acquisita effectively treated with minocycline","volume":"94","author":"Kawase K","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"ref113","first-page":"224","article-title":"Epidermolysis bullosa acquisita with moderately severe Dysphagia due to esophageal strictures","volume":"56","author":"Tu J","year":"2011","journal-title":"Indian J Dermatol"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clindermatol.2011.03.013","article-title":"Immunosuppressive therapy for autoimmune bullous diseases","volume":"30","author":"Meurer M","year":"2012","journal-title":"Clin Dermatol"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jdcr.2015.07.007","article-title":"Mycophenolate mofetil (MMF) in the treatment of epidermolysis bullosa acquisita (EBA) long-term follow-up","volume":"1","author":"Sami N","year":"2015","journal-title":"JAAD Case Rep"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/1346-8138.13546","article-title":"Coexistence of acquired hemophilia A and epidermolysis bullosa acquisita: Two case reports and published work review","volume":"44","author":"Yan TM","year":"2017","journal-title":"J Dermatol"},{"key":"ref117","first-page":"521","article-title":"Intravenous immunoglobulin for treatment of severe acquired bullous epidermolysis refractory to conventional immunosuppressive therapy","volume":"85","author":"Mosqueira CB","year":"2010","journal-title":"An Bras Dermatol"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1468-3083.2011.04205.x","article-title":"Treatment of epidermolysis bullosa acquisita with intravenous immunoglobulin in patients non-responsive to conventional therapy: clinical outcome and post-treatment long-term follow-up","volume":"26","author":"Ahmed AR","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.clim.2008.08.003","article-title":"Subcutaneous immunoglobulin therapy for immunomodulation in a patient with severe epidermolysis bullosa acquisita","volume":"129","author":"Tayal U","year":"2008","journal-title":"Clin Immunol"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.transci.2010.10.006","article-title":"Remission of severe autoimmune bullous disorders induced by long-term extracorporeal photochemotherapy","volume":"43","author":"Sanli H","year":"2010","journal-title":"Transfus Apher Sci"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1684\/ejd.2012.1840","article-title":"Long-term efficacy of extracorporeal photochemotherapy in a patient with refractory epidermolysis bullosa acquisita","volume":"22","author":"Baroudjian B","year":"2012","journal-title":"Eur J Dermatol"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1111\/pde.12526","article-title":"The successful use of extracorporeal photopheresis in a 12-year-old patient with refractory epidermolysis bullosa acquisita","volume":"32","author":"Liszewski W","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.transci.2015.02.005","article-title":"Extracorporeal photopheresis for the treatment of autoimmune diseases","volume":"52","author":"Adamski J","year":"2015","journal-title":"Transfus Apher Sci"},{"issue":"Suppl 1","key":"ref124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jdv.12311","article-title":"Guidelines on the use of extracorporeal photopheresis","volume":"28","author":"Knobler R","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases","volume":"9","author":"Lamberts A","year":"2018","journal-title":"Front Immunol"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly P","year":"2017","journal-title":"Lancet"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/imt-2017-0104","article-title":"Rituximab in pemphigus","volume":"10","author":"Hebert V","year":"2018","journal-title":"Immunotherapy"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"e979","DOI":"10.1111\/j.1365-2230.2009.03608.x","article-title":"Refractory epidermolysis bullosa acquisita: successful treatment with rituximab","volume":"34","author":"Saha M","year":"2009","journal-title":"Clin Exp Dermatol."},{"key":"ref129","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1346-8138.2011.01360.x","article-title":"Successful treatment of epidermolysis bullosa acquisita with rituximab therapy","volume":"39","author":"Kim JH","year":"2012","journal-title":"J Dermatol"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/pde.12006","article-title":"A case of recalcitrant epidermolysis bullosa acquisita responsive to rituximab therapy","volume":"31","author":"McKinley SK","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"ref131","first-page":"795","article-title":"Successful use of combined corticosteroids and rituximab in the treatment of recalcitrant epidermolysis bullosa acquisita","volume":"136","author":"Cavailhes A","year":"2009","journal-title":"Ann Dermatol Venereol"},{"key":"ref132","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/09546634.2016.1179711","article-title":"Long- term results of rituximab-intravenous immunoglobulin combination therapy in patients with epidermolysis bullosa acquisita resistant to conventional therapy","volume":"28","author":"Oktem A","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"ref133","first-page":"289","article-title":"Premonitory epidermolysis bullosa acquisita mimicking eyelid dermatitis: successful treatment with rituximab and protein A immunoapheresis","volume":"11","author":"Kubisch I","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/jdv.12175","article-title":"Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication","volume":"28","author":"Kolesnik M","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.annder.2011.01.013","article-title":"Epidermolysis bullosa acquisita. Guidelines for the diagnosis and treatment. Centres der\u00e9f\u00e9rence des maladies bulleuses auto-immunes. Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie","volume":"138","author":"Prost-Squarcioni C","year":"2011","journal-title":"Ann Dermatol Venereol"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1046\/j.1365-2133.1999.03163.x","article-title":"Ocular involvement in IgA-epidermolysis bullosa acquisita","volume":"141","author":"Bauer JW","year":"1999","journal-title":"B Br J Dermatol"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1046\/j.1365-2133.1997.18191915.x","article-title":"IgA-epidermolysis bullosa acquisita in a child resulting in blindness","volume":"137","author":"Caux F","year":"1997","journal-title":"Br J Dermatol"},{"key":"ref138","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0190-9622(87)70057-7","article-title":"Severe ocular involvement in a patient with epidermolysis bullosa acquisita","volume":"16","author":"Lang Jr PG","year":"1987","journal-title":"JJ Am Acad Dermatol"},{"key":"ref139","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/ced.12009","article-title":"Beware the blistering patient with dysphonia","volume":"38","author":"Benton EC","year":"2013","journal-title":"Clin Exp Dermatol"},{"key":"ref140","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1365-2230.1993.tb01028.x","article-title":"Epidermolysis bullosa acquisita--a case with upper airways obstruction requiring tracheostomy and responding to cyclosporin","volume":"18","author":"Clement M","year":"1993","journal-title":"Clin Exp Dermatol"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/bjd.13224","article-title":"Oesophageal involvement in epidermolysis bullosa acquisita","volume":"172","author":"Ishii N","year":"2015","journal-title":"Br J Dermatol"},{"key":"ref142","first-page":"954","article-title":"Mucosal morbidity in patients with epidermolysis bullosa acquisita","volume":"135","author":"Luke MC","year":"1999","journal-title":"Arch Dermatol"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abd\/v94n2s1\/0365-0596-abd-94-02-s1-0033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:00:46Z","timestamp":1747666846000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0365-05962019000700033&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":142,"journal-issue":{"issue":"2 suppl 1","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["S0365-05962019000700033"],"URL":"https:\/\/doi.org\/10.1590\/abd1806-4841.2019940207","relation":{},"ISSN":["1806-4841","0365-0596"],"issn-type":[{"value":"1806-4841","type":"electronic"},{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}